Victor Peperzak
Overview
Explore the profile of Victor Peperzak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema M
EJHaem
. 2024 Feb;
5(1):141-146.
PMID: 38406516
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab...
2.
Bridging the gap between scientific discoveries and clinical application at the Utrecht Science Park
Peperzak V, Coquet J
Immunol Cell Biol
. 2023 Dec;
102(4):232-234.
PMID: 38058197
Associate Professor Victor Peperzak from the University Medical Center (UMC) Utrecht in the Netherlands discusses the opportunities and challenges of building a research group in the Netherlands. Victor highlights the...
3.
Beltran-Visiedo M, Jimenez-Alduan N, Diez R, Cuenca M, Benedi A, Serrano-Del Valle A, et al.
Mol Oncol
. 2023 Sep;
17(12):2507-2525.
PMID: 37704591
A better understanding of multiple myeloma (MM) biology has led to the development of novel therapies. However, MM is still an incurable disease and new pharmacological strategies are needed. Dinaciclib,...
4.
Greve P, Beishuizen A, Hagleitner M, Loeffen J, Veening M, Boes M, et al.
Front Immunol
. 2023 Aug;
14:1229558.
PMID: 37583696
Introduction: Classical Hodgkin lymphoma (cHL) is the most common pediatric lymphoma. Approximately 10% of patients develop refractory or recurrent disease. These patients are treated with intensive chemotherapy followed by consolidation...
5.
Kimman T, Slomp A, Martens A, Grabherr S, Li S, van Diest E, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36931661
Background: Initial clinical responses with gene engineered chimeric antigen receptor (CAR) T cells in cancer patients are highly encouraging; however, primary resistance and also relapse may prevent durable remission in...
6.
Spaan I, van Nieuwenhuijzen N, Kimman T, Rockx-Brouwer D, Tieland R, Maurice M, et al.
Blood Adv
. 2022 Dec;
7(7):1103-1107.
PMID: 36459495
No abstract available.
7.
Greve P, Meyer-Wentrup F, Peperzak V, Boes M
Immunother Adv
. 2022 Aug;
1(1):ltab001.
PMID: 35919738
After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric...
8.
Rumpret M, von Richthofen H, Peperzak V, Meyaard L
J Exp Med
. 2021 Dec;
219(1).
PMID: 34905019
Pathogen- and damage-associated molecular patterns are sensed by the immune system's pattern recognition receptors (PRRs) upon contact with a microbe or damaged tissue. In situations such as contact with commensals...
9.
Cuenca M, van Nieuwenhuijzen N, Moesbergen L, Bloem A, Minnema M, Peperzak V
Haematologica
. 2021 Dec;
107(4):980-983.
PMID: 34879645
No abstract available.
10.
Spaan I, van de Stolpe A, Raymakers R, Peperzak V
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572895
Multiple myeloma (MM) is a hematological malignancy that is still considered incurable due to the development of therapy resistance and subsequent relapse of disease. MM plasma cells (PC) use NFκB...